A paper published in Nature Communications by a team of researchers from Oxford and North Carolina provides structural insights into human brachyury DNA recognition and discovery of progressible binders for cancer therapy.

Unpacking brachyury

According to the paper’s abstract1, Brachyury is a transcription factor that affects tumour growth of the rare bone cancer chordoma and is implicated in other solid tumours. Brachyury is minimally expressed in healthy tissues, making it a potential therapeutic target. Unfortunately, as a ligandless transcription factor, brachyury has historically been considered undruggable.

To investigate direct targeting of brachyury by small molecules, the researchers determined the structure of human brachyury both alone and in complex with DNA. The structures provide insights into DNA binding and the context of the chordoma associated G177D variant. They used crystallographic fragment screening to identify hotspots on numerous pockets on the brachyury surface.

Finally, the research team performed follow-up chemistry on fragment hits and describe the progression of a thiazole chemical series into binders with low µM potency. Thus, they show that brachyury is ligandable and provide an example of how crystallographic fragment screening may be used to target protein classes that are difficult to address using other approaches.

The Diamond Light Source

This scientific breakthrough was made possible using the Diamond Light Source synchrotron in Didcot, Oxfordshire, a particle accelerator using beams of light reportedly 10,000 times brighter than the sun in the fight against cancer, improved air safety and energy efficiency.

Using this technology, The Guardian reported that the research team has been able to isolate several promising compounds that are now being used to create potential treatments that could attack brachyury and destroy the protein.

The Guardian adds that these techniques now being developed to tackle brachyury and chordoma have wider potential and could be used to improve treatments for other, more common, cancers.

Personal motivation

One of the study’s authors, Professor Paul Workman, was appointed as ICR Chief Executive in November 2024, but his personal motivation to pursue a career in cancer research has always been evident, according to the ICR2. Workman’s father was diagnosed with inoperable bowel cancer while Workman was doing his PhD on new cancer drugs (and which he did not live long enough to see him finish), while Workman’s mother died from a rare bone cancer (a chordoma tumour), having had no real drug options available to her following surgery and radiotherapy. Workman’s latest discoveries points suggest there is a potential drug to beat it.

Workman told The Guardian: “36 years ago, there was little we could do to treat chordoma. There was little understanding of the disease and no drugs were available to help my mother. […] It is thrilling to realise that I am now helping to do something about a disease that killed my mother. It has taken considerable effort by a lot of scientists from centres on both sides of the Atlantic but it has been worth it.”

References
  1. https://www.nature.com/articles/s41467-025-56213-1
  2. https://www.icr.ac.uk/research-and-discoveries/cancer-blogs/detail/science-talk/becoming-a-cancer-patient-has-given-me-extra-perspective-paul-s-story